Lupin settles US patent dispute with Astellas Pharma for $90 million
The settlement resolves Lupin's ‌pending litigation with Astellas and ​enables the company to continue marketing Mirabegron ...
Lupin settles patent dispute with Astellas
USD 90 million, which includes a Prepaid Option Payment of USD 75 million, and (2) a Prepaid Per Unit License Fee for each unit of Lupin Product sold from the date of the settlement through September ...
Hosted on MSN
India's Lupin clears patent hurdle with Astellas Pharma, keeps Mirabegron sales in US
Feb 10 (Reuters) - Indian drugmaker Lupin said on Tuesday it has settled a patent infringement dispute with Japan's Astellas Pharma over the bladder disorder drug Mirabegron, allowing it to continue ...
AOL
India's Zydus Life agrees $120 million settlement with Astellas over bladder drug
Feb 12 (Reuters) - India's Zydus Lifesciences and its U.S. unit will pay $120 million ‌to Astellas Pharma as part of ‌a deal to settle a patent dispute over the Japanese drugmaker's bladder disorder ...
Drug Store News
Astellas reaches settlement agreements with Lupin, Zydus in Myrbetriq patent litigation
Under the terms of the separate settlement agreements with Lupin and Zydus, Astellas will receive a total of $60 million to resolve the litigations from the two companies. In addition, Astellas will ...
Hosted on MSN
India's Zydus, US unit settle mirabegron patent dispute with $120 million payment
Feb 12 (Reuters) - India's Zydus Lifesciences said on Thursday that it and its U.S. unit have agreed to pay $120 million to Astellas Pharma as part of a deal to settle a patent dispute over the ...
AOL
India's Lupin settles US patent dispute with Astellas Pharma for $90 million
FILE PHOTO: The logo of Lupin, India's No. 2 drugmaker, is seen on the facade of its pharmaceutical plant in Verna FILE PHOTO: The logo of Lupin, India's No. 2 drugmaker, is seen on the facade of its ...